New treatment option for Hair Thinning
Official title Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair
ClinicalTrials.gov ID: NCT07041489
What this study is testing
- What it's testing
- The goal of this clinical trial is to test how safe and effective it is to improve hair growth using an active gummy and serum combination treatment when compared to an inactive treatment combination in women with self-perceived thinning hair. The main questions this trial aims to answer are: to confirm using photograph analytics, how much hair growth has increased in a marked area when using active treatment versus inactive treatment, and participants assessment and satisfaction with the hair growth using scaled assessments.
- Time commitment: about 3 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 28 to 65, women only. Healthy volunteers may be eligible.
You may be able to join if
- Female adults between 28-65 years of age with consistent self-perceived thinning hair.
- Ludwig Scale I or II (mild to moderate thinning hair loss), assessed clinically.
- Fitzpatrick Skin Types I to VI.
- Agree to maintain their current diet, medications, exercise routines, hair shampooing, and color treatment frequency for the duration of the study.
- Ability and willingness to comply with the study protocol including regular visits and product application.
You likely can't join if
- Pregnant or lactating or planning to become pregnant.
- Changes in hormonal therapy within 6 months prior to enrollment and throughout the study.
- Use of other medical hair loss treatments (e.g., Minoxidil, Dutasteride, Finasteride, laser or light therapy) within 3 months prior to study start...
- Micro-needling, PRP, or any other physical treatment modality on the scalp (within 6 months prior to study start and throughout the study).
- Use of GLP-1 inhibitors (e.g., Semaglutide) within 6 months prior to study start and throughout the study.
- Known uncontrolled health conditions (e.g., thyroid disease, anemia) that could confound study outcomes.
See the full eligibility criteria
- Female adults between 28-65 years of age with consistent self-perceived thinning hair.
- Ludwig Scale I or II (mild to moderate thinning hair loss), assessed clinically.
- Fitzpatrick Skin Types I to VI.
- Agree to maintain their current diet, medications, exercise routines, hair shampooing, and color treatment frequency for the duration of the study.
- Ability and willingness to comply with the study protocol including regular visits and product application.
- Written informed consent obtained, including written consent to allow photographs to be used as part of the study data and documentation.
- For females of childbearing potential, a negative pregnancy test at screening and commitment to effective contraception throughout the study (oral / implant/ injectable/ transdermal contraceptives, intrauterine device...
- Pregnant or lactating or planning to become pregnant.
- Changes in hormonal therapy within 6 months prior to enrollment and throughout the study.
- Use of other medical hair loss treatments (e.g., Minoxidil, Dutasteride, Finasteride, laser or light therapy) within 3 months prior to study start and throughout the study.
- Micro-needling, PRP, or any other physical treatment modality on the scalp (within 6 months prior to study start and throughout the study).
- Use of GLP-1 inhibitors (e.g., Semaglutide) within 6 months prior to study start and throughout the study.
- Known uncontrolled health conditions (e.g., thyroid disease, anemia) that could confound study outcomes.
- Known sensitivity to any of the ingredients in the study medication.
- In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
- Subject has any conditions, findings in history, physical exam or laboratory assessments, which in the opinion of the investigator, would exclude the subject from continuing in this study.
- Treatment with an experimental drug, biologic or device within 12 weeks of the screening visit.
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Aventura, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 3 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling female, 28 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Aventura, Florida, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.